Business Context and Reporting Period
This Form 8-K is a current report filed by AgeX Therapeutics, Inc. (referred to in the request metadata as Serina Therapeutics, Inc.) on March 21, 2019. The filing discloses the entry into a material definitive agreement regarding a new sublease for office and research facilities.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or margin data. Specific financial obligations disclosed include:
- Base Monthly Rent: $35,866.50 for the initial 12 months, increasing to $36,942.50 thereafter.
- Equipment Purchase: $40,000 paid to the sublessor for laboratory and other equipment.
- Additional Costs: The company is responsible for real property taxes, insurance, and operating expenses pertaining to the building.
- Lease Term: Expires on December 31, 2020.
Material Changes
The primary material change is the execution of a sublease for approximately 23,911 square feet of space at 965 Atlantic Avenue, Alameda, California. This facility is intended to serve as the company's principal offices and research laboratory. The company plans to construct a cGMP laboratory facility at this location for the manufacture of cell lines and cell-based product candidates.
Outlook, Risks, and Contingencies
Operational Plans: The company intends to utilize the new facility for research and the development of cell-based products.
Risks and Default Conditions: The sublease outlines specific events of default, including:
- Failure to pay rent within 10 days of notice (or without notice if this occurs three or more times in 12 months).
- Material default on other lease terms continuing for 30 days after notice.
- Bankruptcy, insolvency, or appointment of a receiver.
- Abandonment of the facility.
Liabilities: The company has agreed to indemnify the sublandlord against liabilities arising from hazardous materials and must maintain specific liability insurance.
Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from anticipated results due to various risk factors.
Investor Verification Checklist
- Verify the company's current cash position to ensure it can meet the monthly rent obligation of approximately $36,000 plus operating expenses.
- Confirm the status of the master landlord's approval, which is a condition precedent for the commencement of the sublease.
- Review the upcoming Form 10-Q for the three months ending March 31, 2019, to access the full text of the sublease and master lease.
- Assess the capital requirements for the planned construction of the cGMP laboratory facility.